During the last session, TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares were 1.97 million, with the beta value of the company hitting 2.20. At the end of the trading day, the stock’s price was $23.35, reflecting an intraday gain of 1.04% or $0.24. The 52-week high for the TGTX share is $25.38, that puts it down -8.69 from that peak though still a striking 72.33% gain since the share price plummeted to a 52-week low of $6.46. The company’s market capitalization is $3.62B, and the average intraday trading volume over the past 10 days was 3.52 million shares, and the average trade volume was 2.89 million shares over the past three months.
TG Therapeutics Inc (TGTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.56. TGTX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TG Therapeutics Inc (NASDAQ:TGTX) trade information
TG Therapeutics Inc (TGTX) registered a 1.04% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.04% in intraday trading to $23.35, hitting a weekly high. The stock’s 5-day price performance is -6.86%, and it has moved by 21.55% in 30 days. Based on these gigs, the overall price performance for the year is 127.36%. The short interest in TG Therapeutics Inc (NASDAQ:TGTX) is 32.72 million shares and it means that shorts have 10.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies a decrease of -1.52% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16 and $49 respectively. As a result, TGTX is trading at a discount of -109.85% off the target high and 31.48% off the low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Statistics show that TG Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. TG Therapeutics Inc (TGTX) shares have gone up 32.44% during the last six months, with a year-to-date growth rate more than the industry average at 44.44% against 14.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -97.30% this quarter and then jump 180.00% in the quarter after that. In the rating firms’ projections, revenue will increase 40.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 81.23M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 98.42M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 46.56M and 43.97M respectively. In this case, analysts expect current quarter sales to grow by 74.50% and then jump by 123.80% in the coming quarter.
While earnings are projected to return -43.06% in 2024.
TGTX Dividends
TG Therapeutics Inc is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc insiders own 9.59% of total outstanding shares while institutional holders control 60.96%, with the float percentage being 67.43%. VANGUARD GROUP INC is the largest shareholder of the company, while 327.0 institutions own stock in it. As of 2024-06-30, the company held over 13.69 million shares (or 9.3645% of all shares), a total value of $243.58 million in shares.
The next largest institutional holding, with 11.39 million shares, is of BLACKROCK INC.’s that is approximately 7.7891% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $202.6 million.
